

# $\alpha$ -Synuclein Fibrils , Human

## Cat. No. CSR-SYN03

Updated on Nov. 10th, 2021

% This product is manufactured under license from Takashi Nonaka, Ph.D. and Masato Hasegawa, Ph.D. of Department of Dementia and Higher Brain Function, Tokyo Metropolitan Institute of Medical Science.

## [ ] Introduction

#### www.cosmobiousa.com

Dementia is a disease that causes memory and judgement loss, there is no fundamental treatment developed for it. Years of scientific research has proven that protein aggregation occurs in the degeneration part of the brain for many neurodegenerative diseases including dementia, indicating appearance of this aggregation is closely related to these diseases development and progression.

Aggregation occurs when normal protein forms abnormal structure for particular reasons and accumulates in the cell, which each disease has different aggregating protein. It is known that protein called " $\alpha$  -Synuclein" forms abnormal structure in Parkinson Disease / Lewy Body Dementia / Multiple system atrophy patient brain.

## [II] Product Information

This product contains *in vitro* sonicated  $\alpha$  - Synuclein Fibrils (Human, Recombinant, E.coli). It is confirmed maintaining seed activity in vitro.

Storage: -80℃

Description	Quantity	Purity	Suspending solvent
α -Synuclein Fibrils	0.1 mg	≧ 90%	Saline
(Human)	(conc. 1 mg/mL 、100 μL)	(SDS-PAGE)	

<sup>\*</sup> CAUTION: Prior to disposing F-  $\alpha$  Syn, please autoclave (134 °C 20 min.), or add SDS (>3%) prior to autoclave (121 °C, 20min.). If above condition cannot be matched, please dispose accordingly to your local rules and regulations.

This product does not contain preservatives. Please add NaN3 (0.1%) etc. if necessary.

## [III] References

- [1] Conversion of wild-type alpha-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant. Yonetani M, Nonaka T, Masuda M, Inukai Y, Oikawa T, Hisanaga S, Hasegawa M. J Biol Chem. 2009 Mar 20;284(12):7940-50 (PMID: 19164293)
- [2] Seeded aggregation and toxicity of {alpha}-synuclein and tau: cellular models of neurodegenerative diseases. Nonaka T, Watanabe ST, Iwatsubo T, Hasegawa M. J Biol Chem. 2010 Nov 5;285(45):34885-98 (PMID: 20805224)
- [3] Prion-like spreading of pathological α -synuclein in brain.
  Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H, Mann DM, Hasegawa M.
  Brain. 2013 Apr;136(Pt 4):1128-38 (PMID: 23466394)

1

#### www.cosmobiousa.com

1 MG

## [IV] Related products

ated products		
Description	Cat. No.	Quantity
lpha -Synuclein Aggregation Assay Kit	CSR-SYN01	1 KIT (300 TEST)
Amyloid Fluorescent Staining Kit	CSR-SYN02	1 KIT (100 TEST)
Human $\alpha$ -Synuclein Fibrils	CSR-SYN03	0.1 MG
Human $\alpha$ -Synuclein, Recombinant, E.coli	CSR-SYN04	0.1 MG
Human a -Synaclein, Recombinant, E.con		1 MG
Mouse $\alpha$ -Synuclein Fibrils	CSR-SYN05	0.1 MG
Mouse $\alpha$ -Synuclein, Recombinant, E.coli	CSR-SYN06	0.1 MG
Mouse a -synaclein, necombinant, E.con		1.46



#### [JAPAN]

TOYO EKIMAE BLDG. 2-20, TOYO 2-CHOME, KOTO-KU. TOKYO 135-0016, JAPAN Phone: +81-3-5632-9610 FAX: +81-3-5632-9619 URL: https://www.cosmobio.co.jp/





[Outside Japan] 2792 Loker Ave West, Suite 101 Carlsbad, CA 92010, USA email: info@cosmobiousa.com URL: www.cosmobiousa.com Phone/FAX: (+1) 760-431-4600